Matthew H. Kulke, MD, MMSc of Dana-Farber and Harvard Medical School explains whether or not somatostatin analogues were needed to see efficacy in treatment for carcinoid syndromes. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.
Telotristat and Somatostatin Analogue in Advanced Neuroendocrine Tumors
